Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 144, Issue 6, 2007, Pages 809-815

  Dolžan, Vita ^a   Plesničar, Blanka Kores ^b   Serretti, Alessandro ^c   Mandelli, Laura ^c   Zalar, Bojan ^d   Koprivšek, Jure ^b   Breskvar, Katja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Antipsychotics; DRD1; DRD2; Extrapyramidal side effects; Schizophrenia

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; RISPERIDONE; THIORIDAZINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

AKATHISIA; ARTICLE; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; PARKINSONISM; POSITIVE SYNDROME; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; EXTRAPYRAMIDAL TRACTS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 34548699668     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30544     Document Type: Article

References (70)

1. Abdolmaleky HM, Thiagalingam S, Wilcox M. 2005. Genetics and epigenetics in major psychiatric disorders: Dilemmas, achievements, applications, and future scope. pp. 149-60.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, 4th Edition. Washington, DC: American Psychiatric Association.
3. Arinami T, Gao M, Hamaguchi H, Toru M. 1997. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-582.
4. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. 1995. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346:281-282.
5. Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, Kerwin RW. 1998. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 8:481-484.
6. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW. 2000. Pharmacogenetic prediction of clozapine response. Lancet 355:1615-1616.
7. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
8. Bazire S. 2003. Psychotropic Drug Directory 2003/2004. Salisbury: Fivepin Publishing Limited. p 180.
9. Benson MA, Sillitoe RV, Blake DJ. 2004. Schizophrenia genetics: Dysbindin under the microscope. Trends Neurosci 27:516-519.
10. Chong SA, Tan EC, Tan CH, Mythily, Chan YH. 2003. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 116:51-54.
11. Chotai J, Serretti A, Lorenzi C. 2005. Interaction between the tryptophan hydroxylase gene and the serotonin transporter gene in schizophrenia but not in bipolar or unipolar affective disorders. Neuropsychobiology 51:3-9.
12. Cichon S, Nothen MM, Stober G, Schroers R, Albus M, Maier W, Rietschel M, Korner J, Weigelt B, Franzek E, Wildenauer D, Fimmers R, Propping P. 1996. Systematic screening for mutations in the 5′-regulatory region of the human dopamine D1 receptor (DRD1) gene in patients with schizophrenia and bipolar affective disorder. Am J Med Genet 67:424-428.
13. Cohen J. 1988. Statistical power analysis for the behavioral sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates. pp 8-14.
14. Cooper SJ, Dourish CT. 1990. An introduction to the concept of stereotypy and a historical perspective on the role of brain dopamine. In: Cooper SJ, Dourish CT, editors. "Neurobiology of stereotyped behavior". Oxford: Clarendon Press. pp 1-24.
15. Corfas G, Roy K, Buxbaum JD. 2004. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 7:575-580.
16. Dubertret C, Gouya L, Hanoun N, Deybach JC, Ades J, Hamon M, Gorwood P. 2004. The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr Res 67:75-85.
17. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
18. Feng J, Sobell JL, Heston LL, Cook EH Jr, Goldman D, Sommer SS. 1998. Scanning of the dopamine D1 and D5 receptor genes by REF in neuropsychiatric patients reveals a novel missense change at a highly conserved amino acid. Am J Med Genet 81:172-178.
19. Goetz CG, Burke PF, Leurgans S, Berry-Kravis E, Blasucci LM, Raman R, Zhou L. 2001. Genetic variation analysis in parkinson disease patients with and without hallucinations: Case-control study. Arch Neurol 58:209-213.
20. Guy W. 1976. ECDEU Assessment manual for psychopharmacology: revised. In: 76-338DPNA (ed), Rockville, MD, pp 534-537.
21. Himei A, Koh J, Sakai J, Inada Y, Akabame K, Yoneda H. 2002. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and - 141C Ins/Del polymorphisms. Psychiatry Clin Neurosci 56:97-102.
22. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J. 2001. Association analysis between two functional dopamine D2 receptor gene polymorphisms and schizophrenia. Am J Med Genet 105:176-178.
23. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M. 1993. A structural polymorphism of human dopamine D2 receptor, D2(Ser311->Cys). Biochem Biophys Res Commun 196:1369-1375.
24. Jeste DV, Caligiuri MP. 1993. Tardive dyskinesia. Schizophr Bull 19:303-315.
25. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC. 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296.
26. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J. 2002. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 7:695-705.
27. Kane JM, Smith JM. 1982. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473-481.
28. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
29. Kay SR, Opler LA, Lindenmayer JP. 1989. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry (Suppl):59-67.
30. Kendler KS. 2005. "A gene for...": the nature of gene action in psychiatric disorders. Am J Psychiatry 162:1243-1252.
31. Kojima H, Ohmori O, Shinkai T, Terao T, Suzuki T, Abe K. 1999. Dopamine D1 receptor gene polymorphism and schizophrenia in Japan. Am J Med Genet 88:116-119.
32. Kores Plesnicar B, Zalar B, Breskvar K, Dolzan V. 2006. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 20:829-833.
33. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH. 2004. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol 7:461-470.
34. Lane HY, Lee CC, Liu YC, Chang WH, Chang YC, Lu CT, Huang CH. 2005. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6:139-149.
35. Lewis DA. 2002. Neural circuitry approaches to understanding the pathophysiology of schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. "Neuropsychopharmacology: The fifth generation of progress". Philadelphia: Lippincott Williams & Wilkins. pp 729-743.
36. Maier W, Hofgen B, Zobel A, Rietschel M. 2005. Genetic models of schizophrenia and bipolar disorder: Overlapping inheritance or discrete genotypes? Eur Arch Psychiatry Clin Neurosci 255:159-166.
37. Malhotra AK, Murphy GM Jr, Kennedy JL. 2004. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796.
38. Maziade M, Bouchard S, Gingras N, Charron L, Cardinal A, Roy MA, Gauthier B, Tremblay G, Cote S, Fournier C, Boutin P, Hamel M, Merette C, Martinez M. 1996. Long-term stability of diagnosis and symptom dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence. II: Postnegative distinction and childhood predictors of adult outcome. Br J Psychiatry 169:371-378.
39. Mihara K, Kondo T, Suzuki A, Yasui N, Ono S, Otani K, Kaneko S. 2001. No relationship between - 141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. Psychiatry Res 101:33-38.
40. Mihara K, Kondo T, Higuchi H, Takahashi H, Yoshida K, Shimizu T, Kaneko S. 2002. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: A preliminary finding. Am J Med Genet 114:693-695.
41. Mossman D. 1997. A decision analysis approach to neuroleptic dosing: Insights from a mathematical model. J Clin Psychiatry 58:66-73.
42. Nakazono Y, Abe H, Murakami H, Koyabu N, Isaka Y, Nemoto Y, Murata S, Tsutsumi Y, Ohtani H, Sawada Y. 2005. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients. Int J Clin Pharmacol Ther 43:163-171.
43. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A. 1998. Functional polymorphism of -141C Ins/Del in the dopamine D-2 receptor gene promoter and schizophrenia. Psychiatry Res 81:117-123.
44. Owen MJ, Sanders AR, Duan J, Gejman PV. 2004. Genomic approaches to schizophrenia. Complexities in psychiatric genetics. Int Rev Psychiatry 16:S2-S7.
45. Pae CU, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH, Park HR, Yang S, Serretti A. 2003. Polymorphism of the serotonin transporter gene and symptomatic dimensions of schizophrenia in the Korean population. Neuropsychobiology 47:182-186.
46. Pedro BM, Pilowsky LS, Costa DC, Hemsley DR, Ell PJ, Verhoeff NP, Kerwin RW, Gray NS. 1994. Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia. Psychol Med 24:423-429.
47. Pierre JM. 2005. Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention and management. Drug Saf 28:191-208.
48. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney WE Jr, Fallon JH, Kennedy JL. 2003. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 8:109-113.
49. Rybakowski JK, Borkowska A, Czerski PM, Kapelski P, Dmitrzak-Weglarz M, Hauser J. 2005. An association study of dopamine receptors polymorphisms and the Wisconsin Card Sorting Test in schizophrenia. J Neural Transm 112:1578-1582. Epub 2005 Mar 23.
50. Sanders AR, Duan J, Gejman PV. 2004. Complexities in psychiatric genetics. Int Rev Psychiatry 16:284-293.
51. Sato M, Soma M, Nakayama T, Kanmatsuse K. 2000. Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension 36:183-186.
52. Scharfetter J. 2001. Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2:251-261.
53. Scharfetter J. 2004. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia - an update. Pharmacogenomics 5:691-698.
54. Seeman MV. 1981. Pharmacologic features and effects of neuroleptics. Can Med Assoc J 125:821-826.
55. Segman RH, Ebstein RP, Heresco-Levy U, Gorfine M, Avnon M, Gur E, Nemanov L, Lerer B. 1997. Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene. Psychiatric Genet 7:75-78.
56. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B. 1999. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 4:247-253.
57. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B. 2001. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6:225-229.
58. Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M, Yakir A, Greenberg D, Strous R, Lerner A, Shelevoy A, Lerer B. 2003. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 3:277-283.
59. Serretti A, Macciardi F, Smeraldi E. 1998. Dopamine receptor D2 Ser Cys311 variant associated with disorganized symptomatology of schizophrenia. Schizophr Res 34:207-210.
60. Serretti A, Lattuada E, Lorenzi C, Lilli R, Smeraldi E. 2000a. Dopamine receptor D2 ser/cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Mol Psychiatry 5:270-274.
61. Serretti A, Lilli R, Lorenzi C, Smeraldi E. 2000b. Further evidence supporting the association between the dopamine receptor D2 Ser/Cys311 variant and disorganized symptomatology of schizophrenia. Schizophr Res 43:161-162.
62. Serretti A, Artioli P, Quartesan R. 2005. Pharmacogenetics in the treatment of depression: Pharmacodynamic studies. Pharmacogenet Genom 15:61-67.
63. Serretti A, Calati R, Mandelli L, De Ronchi D. 2006. Serotonin transporter gene variants and behaviour: A comprehensive review. Curr Drug Targets. 7:1659-1669.
64. Shinkai T, Ohmori O, Suzuki T, Kojima H, Hori H, Terao T, Nakamura J. 2000. Polymorphisms of tryptophan hydroxylase gene and the symptomatology of schizophrenia: An association study. Psychiatr Genet 10:165-171.
65. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
66. Strous RD, Lapidus R, Viglin D, Kotler M, Lachman HM. 2006. Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosci Lett. 393:170-173.
67. Tiilikainen A, Fischer G, Grubic Z, Gyodi E, Ivaskova E, Jungerman M, Kastelan A, Korinkova P, Martinovic I, Sochnevs A, Suciu-Foca N, Vidan-Jeras B. 1997. Anthropological features of the East European region. In: Charron D, editor. "HLA: Genetic diversity of HLA functional and medical implication. Proceedings of the 12th international histocompatibility workshop and conference". Vol. 1 Paris: EDK, Medical and Scientific International Publisher. pp 307-313.
68. Vidan-Jeras B, Jurca B, Dolzan V, Jeras M, Breskvar K, Bohinjec M. 1998. Caucasian Slovenian normal. In: Gjertson DW, Terasaki PI, editors. "HLA 1998". Lenexa: American society for histocompatibility and immunogenetics. pp 180-181.
69. Woods SW. 2003. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663-667.
70. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L. 2005. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 376:1-4. Epub 2004 Dec 2.